The University of Edinburgh
Role of adhesion proteins in immune modulation of glioblastoma
Abstract
dc:description.abstractGlioblastoma (GBM) is a grade 4 diffuse glioma with an average survival of just 15 months with standard of care therapies (surgical resection followed by concurrent temozolomide and radiotherapy). Recent studies leveraging single cell sequencing techniques have highlighted a heterogenous immune landscape in GBM tumour microenvironment (TME), mainly comprised of brain-resident microglia and infiltrating bone marrow-derived macrophages. The role of adhesion proteins, namely focal adhesion kinase (FAK), in modulating the immune environment in multiple cancers has been reported. However, the role of adhesion proteins in mediating immune cell infiltration into GBM TME and regulation of immune phenotypes remains unclear. Firstly, this study aims to immunologically characterise three syngeneic GBM models to ascertain their suitability for assessing intratumoural and systemic immune populations. Multiparametric flow cytometry was employed to do so and concluded key differences in the abundance of systemic immune infiltration into brain tumours as well as changes to immune composition in systemic tissues across the three models assessed. Additionally, two of the syngeneic models were subject to bulk RNA sequencing which identified distinct transcriptional landscapes. Following on from this, the immunomodulatory role of two adhesion proteins, integrin-linked kinase (ILK) and FAK, were investigated in vivo by utilising both genetic deletion models and pharmacological inhibition. It was concluded that inhibiting FAK’s kinase activity with a clinically tested small molecule compound (VS-4718) produced significant changes to myeloid cell abundance and phenotype whereas intratumoural genetic deletion of ILK or FAK had little immunological consequences. The effects of VS-4718 on integrin expression in immune cells was assessed using an integrin-focussed flow cytometry panel and revealed inhibitor-driven changes to VLA-4 expression on systemic populations of myeloid cells, suggesting their ability to bind to the vasculature via VCAM may be altered. Finally, in vitro investigation into the mechanism behind VS-4718-driven changes to myeloid cells was conducted to assess whether the drug affected myeloid cell recruitment to tumours by altering the secretome of glioma stem cells. Additionally, the direct effect of VS-4718 on myeloid cell adhesion, migration and morphology in vitro was assessed. Altogether, this work provides an immunological overview of both intratumoural and systemic tissues in multiple widely used mouse models of GBM which may guide future immune-focussed pre-clinical GBM research. Additionally, this work highlights a novel role for the clinically tested FAK inhibitor VS-4718 in altering systemic myeloid populations in the pre-clinical setting.
Degree
thesis:*- Grantor dc:publisher
- The University of Edinburgh
- Year dc:date.issued
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Black, Annabel
- Advisors dc:contributor.advisor
-
- Brunton, Val
- Webb, Emily
- Gentek, Rebecca
Subjects
dc:subject × 5Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- http://dx.doi.org/10.7488/era/6792